This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment of acute lymphoblastic leukaemia

Authoring team

Treatment of ALL consists of the following:

  • remission induction phase
  • intensification (or consolidation) phase
  • continuation therapy to eliminate residual disease (1)

The only exception to this is in patients with mature B cell ALL where short term intensive chemotherapy (including high-dose methotrexate, cytarabine, and cyclophosphamide are used) (1).

Therapy directed at CNS is started early in the clinical course which is aimed at preventing relapses attributable to leukemic cells sequestered in this site (1).

Children respond well to treatment:

  • 95% achieve complete remission
  • 50-60% of whom are cured with postremission chemotherapy

Fewer advances have been achieved in adults:

  • 80% achieve complete remission
  • about 35% achieve long-term disease-free survival

Notes:

  • allogenic transplantation has shown clear benefits in the following patients who are at high risk of ALL:
    • individuals with Philadelphia chromosome-positive disease
    • poor initial response to treatment (1)
    • it is also useful in improving the outcome of adults with the t(4;11) subtype of ALL (but the benefits in infants with this genotype is controversial) (1).

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.